List view / Grid view
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further…
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
Research into the structure of the drug-integrin complex has enabled the creation of drugs which inhibit integrin as effectively as currently used compounds, without causing excessive bleeding.
A new process for producing organoids allows researchers to explore intestinal epithelium in isolation and could allow for the development of improved targeted treatments of diseases.
Research has found that bile acids, converted by gut microbes, act as inflammatory regulators in IBD by modulating the differentiation of T cells in the gut.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
A study has found a new molecular process in mice that causes autoimmune diseases and has opened avenues for developing more effective autoimmune therapies.
Researchers have found that a type of T cell, called a Tr1 cell, could work as a therapeutic strategy for inflammatory bowel disease in children.
Researchers have reported finding on an epigenetic signature in patient cells that appears to predict inflammation risk in Crohn's disease...
Researchers propose a novel approach to manipulate genes that may hold the key to the future of personalised medicine...
